Pan‐ TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity
The Journal of Pathology: Clinical Research · 2026-07 · 12 (4)
DOI: 10.1002/2056-4538.70105 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 01.07.2026. Verfasst von Yinan Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Hospital of China Medical University, Shenyang, PR China. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, Biomarkers, Tumor, Receptor, trkA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tropomyosin receptor kinase (TRK) fusions are actionable oncogenic drivers, and pan‐TRK immunohistochemistry (IHC) serves as a reliable screening tool for NTRK gene aberrations. However, the expression profile and clinical significance of pan‐TRK in meningiomas remain unclear. This study aimed to characterize pan‐TRK expression, its correlation with clinicopathological features, and underlying NTRK rearrangement status in meningiomas. We retrospectively analyzed 70 primary intracranial tumor specimens, including 50 meningiomas (21 WHO grade 1, 26 grade 2, and 3 grade 3) and 20 non‐meningioma CNS tumors (9 solitary fibrous tumors, 6 hemangioblastomas, and 5 schwannomas) from the First Affiliated Hospital of China Medical University (2020–2022). Pan‐TRK IHC was performed using the Ventana EPR17341 antibody, with fluorescence in situ hybridization (FISH) validating NTRK gene aberrations in positive cases. Clinicopathological correlations were analyzed using chi‐square/Fisher's exact tests and Spearman's rank correlation. Pan‐TRK immunoreactivity was detected in 12/50 (24.0%) meningiomas, predominantly with cytoplasmic staining (75.0%). Positivity was significantly higher in high‐grade (WHO 2/3) meningiomas (7/29, 46.7% versus 3/21, 14.3% in grade 1; p = 0.031) and tumors with Ki‐67 index ≥5% (7/15, 46.7% versus 5/35, 14.3% in Ki‐67
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Hospital of China Medical University, Shenyang, PR China.
- Department of Pathology, College of Basic Medical Sciences of China Medical University, Shenyang, PR China.
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
ORCID-Profile: Xuyong Lin
Zitieren
APA
Zhu, Y., Sun, M., Lu, W., Wang, Z., Xi, H., Song, Y., Xu, H., & Lin, X. (2026). Pan‐ TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity. The Journal of Pathology: Clinical Research, 12(4). https://doi.org/10.1002/2056-4538.70105
Vancouver
Zhu Y, Sun M, Lu W, Wang Z, Xi H, Song Y, et al. Pan‐ TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity. The Journal of Pathology: Clinical Research. 2026;12(4). doi:10.1002/2056-4538.70105
BibTeX
@article{Zhu2026,
author = {Zhu, Yinan and Sun, Mingfang and Lu, Wanchen and Wang, Ziyue and Xi, Haiyan and Song, Yan and Xu, Hongtao and Lin, Xuyong},
title = {Pan‐ TRK expression and NTRK gene aberrations in meningiomas: association with tumor grade and proliferative activity},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {4},
doi = {10.1002/2056-4538.70105}
}
EUVIMED